Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 April;158(2) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 April;158(2):65-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

THERAPEUTICAL NOTES   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 April;158(2):65-8

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: Italian

Hormone replacement treatment in menopause. Current approaches

Grio R., Curti A., Geranio R., Piacentino R.

Università degli Studi - Torino, Dipartimento di Scienze Ginecologiche Ostetriche, Cattedra C, Unità di Semeiotica Ostetrica e Ginecologica


PDF


There is now no question that during the post-menopausal period a woman’s life is severely disturbed by vasomotor disorders, changes in psychoemotional balance, symptoms of a trophic nature affecting the skeletal and genito-urinary systems and a marked increase in the risk-of ischemic cardiopathy. The striking efficacy of prompt and appropriate hormone replacement treatment (HRT) in delaying and to a large extent eliminating the consequences of oestrogen deficiencies on the body has been amply demonstrated. Following numerous studies carried out on this aspect, it can be said that HRT using estrogens and progestins, as is now widely used in both America and Europe, allows the following results to be achieved: in the short term, a marked improvement in the quality of life and in particular sexual activity through increased libido, renewed vaginal lubrication and facilitated orgasm; in the long term it offers three advantages: prevention of osteoporosis, cardiovascular disease, vascular dementia and some types of Alzheimer’s disease. There is no increase in the risk of breast tumour in patients receiving up to 5 years’ treatment, whereas the risk is enhanced after this period. The continuation of HRT for a longer period should be reserved to women in premature menopause or with a high risk of osteoporotic fractures or fatal coronary attacks.

top of page